Company profile IRON

Disc Medicine Inc
disc medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. focused on the hepcidin pathway, the master regulator of iron metabolism, disc is advancing first-in-class therapies to transform the treatment of hematologic diseases.
Quarter analysis & expected interestLast update: February 09 2024 11:11:14.

After 39 days of this quarter the interest is at 240.0. Based on that we can calculate that during remaining 52 days it will total up to 560.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019315
434
37.8% QoQ
419
-3.5% QoQ
377
-10.0% QoQ
2020 360
14.3% YoY -4.5% QoQ
448
3.2% YoY 24.4% QoQ
456
8.8% YoY 1.8% QoQ
355
-5.8% YoY -22.1% QoQ
2021 366
1.7% YoY 3.1% QoQ
369
-17.6% YoY 0.8% QoQ
408
-10.5% YoY 10.6% QoQ
389
9.6% YoY -4.7% QoQ
2022 527
44.0% YoY 35.5% QoQ
531
43.9% YoY 0.8% QoQ
570
39.7% YoY 7.3% QoQ
514
32.1% YoY -9.8% QoQ
2023 528
0.2% YoY 2.7% QoQ
812
52.9% YoY 53.8% QoQ
664
16.5% YoY -18.2% QoQ
775
50.8% YoY 16.7% QoQ
2024 240
-54.5% YoY -69.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Disc Medicine search interestLast update: February 09 2024 11:11:12.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 11:11:37.

The average 5 years interest of Disc Medicine was 37.77 per week.
The last year interest of Disc Medicine compared to the last 5 years has changed by 43.63%.
The interest for Disc Medicine is trending.
The last year interest is quite higher compared to 5 years ago. It has increased by 67.33%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Disc Medicine Disc Medicine stock to provide analysis

Correlation between past revenue and Disc Medicine Disc Medicine stock search interest

There is not enough data for Disc Medicine Disc Medicine stock to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Disc Medicine Disc Medicine stock to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Disc Medicine news to provide analysis

Correlation between past revenue and Disc Medicine news search interest

There is not enough data for Disc Medicine news to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Disc Medicine news to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Disc Medicine CEO to provide analysis

Correlation between past revenue and Disc Medicine CEO search interest

There is not enough data for Disc Medicine CEO to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Disc Medicine CEO to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Disc Medicine pipeline to provide analysis

Correlation between past revenue and Disc Medicine pipeline search interest

There is not enough data for Disc Medicine pipeline to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Disc Medicine pipeline to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Disc Medicine hematology to provide analysis

Correlation between past revenue and Disc Medicine hematology search interest

There is not enough data for Disc Medicine hematology to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Disc Medicine hematology to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Disc Medicine biopharmaceutical to provide analysis

Correlation between past revenue and Disc Medicine biopharmaceutical search interest

There is not enough data for Disc Medicine biopharmaceutical to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Disc Medicine biopharmaceutical to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Disc Medicine heme biosynthesis. to provide analysis

Correlation between past revenue and Disc Medicine heme biosynthesis. search interest

There is not enough data for Disc Medicine heme biosynthesis. to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Disc Medicine heme biosynthesis. to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for IRON
Earnings date: 2024-03-29 After close
Company name: Disc Medicine Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-20T17:52:10-07:00

GlobeNewswire
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

2026-10-20T18:08:38.947010072Z

Analyst Upgrades
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $92

2026-10-20T15:38:11.998569739Z

Analyst Upgrades
Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $115

2026-10-20T13:54:00.370955259Z

Analyst Upgrades
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $124

2026-10-20T08:59:00-04:00

PR Newswire
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

2026-10-20T12:35:27.528411973Z

Analyst Upgrades
Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $110

2026-10-19T13:01:00-07:00

GlobeNewswire
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants

2026-10-19T17:51:11.149768667Z

Analyst Upgrades
BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120

2026-10-19T14:34:49.550996822Z

Analyst Upgrades
Cantor Fitzgerald Maintains Overweight on Disc Medicine, Raises Price Target to $170

2026-10-19T08:00:00-04:00

Earnings Call Transcripts
DISC MEDICINE CORPORATE CALL - DISC MEDICINE INC

2026-10-19T04:00:00-07:00

GlobeNewswire
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)

2026-10-18T14:00:00-07:00

GlobeNewswire
Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)

2026-10-02T15:55:00-04:00

PR Newswire
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

2026-09-26T18:00:00-04:00

PR Newswire
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

2026-09-16T22:16:00-04:00

PR Newswire
Rosen Law Firm Encourages Disc Medicine, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - IRON